CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
GlaxoSmithKline said on Thursday that U.S. regulators have approved the use of its drug Hycamtin in combination with cisplatin for the treatment of cervical cancer that can't be treated with surgery or radiation therapy. The Food and Drug Administration approval is based on late-stage results that demonstrated a survival advantage by using Hycamtin in combination with cisplatin compared with cisplatin alone. The company is currently developing a vaccine for the human papilloma virus, the leading cause of cervical cancer. Hycamtin is currently marketed in the United States for the treatment of a type of lung cancer. (Reuters)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Queer Youth Negatively Affected by Anti-LGBTQ+ Laws, Debates: Trevor Project Poll
January 20 2023 5:18 PM
Emanuele Crialese on His Autobiographical Coming-of-age Trans Film, L'immensitÃ
January 19 2023 8:02 PM
CPAC's Matt Schlapp & Wife Sued By GOP Staffer For Sex Harassment, Defamation
January 19 2023 5:13 PM